

First Clinical Research Stock Index (FCRI)

Welcome to the inaugural edition of the First Clinical Research Stock Index (FCRI). FCRI includes all 11 publicly-traded clinical research stocks. Three other indices are also displayed for comparison. If you know of a pharmaceutical industry sector index, please contact us.

Market Activity

FCRI launched in the month of October with a sharp 7.5% drop. ICON, Datatrack International, and Kendle International showed the largest declines. Only PAREXEL International and Covance showed increases.

Pharmaceutical, biotech and general market indices also declined, but to a lesser extent.

Notes on Indices

FCRI and pharmaceutical indices are calculated as the mean average percentage change from baseline, dividends excluded, adjusted for stock splits. In other words, the indices are not weighted for stock price or market capitalization. Index components may change from time to time based on new listings, mergers and other factors. Index values are approximate only.

- **FCRI Clinical Research Index.** Components are Bio-Imaging Technologies, Covalent Group, Covance, Datatrak International, eResearchTechnology, ICON, Kendle International, MDS Pharma Services, Parexel International, Phase Forward, PPD and SFBC International
- **FCRP Pharmaceutical Industry Index.** Components are Abbott Laboratories, AstraZeneca, Eli Lilly & Co., GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Sanofi-Aventis and Wyeth.
- **NASDAQ Biotechnology Index (NBI).** Only NASDAQ listings are included. Available at http://dynamic.nasdaq.com/dynamic/nasdaqbiotech_activity.stm
- **S&P Index.** Available at <http://money.cnn.com/data/markets/sandp/>

